Old West Investment Management LLC Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Old West Investment Management LLC lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 617.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340,441 shares of the biopharmaceutical company's stock after acquiring an additional 292,976 shares during the period. Amicus Therapeutics accounts for 1.3% of Old West Investment Management LLC's holdings, making the stock its 24th largest position. Old West Investment Management LLC owned about 0.11% of Amicus Therapeutics worth $3,636,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in Amicus Therapeutics by 20.1% during the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company's stock worth $162,713,000 after purchasing an additional 2,307,385 shares during the last quarter. William Blair Investment Management LLC lifted its stake in shares of Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock worth $128,993,000 after buying an additional 1,477,084 shares in the last quarter. Fiera Capital Corp boosted its position in Amicus Therapeutics by 1.1% during the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock worth $52,382,000 after acquiring an additional 58,113 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Amicus Therapeutics by 14.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company's stock valued at $29,964,000 after acquiring an additional 378,999 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Amicus Therapeutics by 17.9% in the 2nd quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company's stock valued at $22,558,000 after acquiring an additional 345,117 shares during the last quarter.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $9,398,532.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 22,500 shares of company stock worth $253,275. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group began coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a "buy" rating and a $18.00 price target for the company. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 price target on shares of Amicus Therapeutics in a report on Friday, September 20th. Morgan Stanley cut their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday, August 16th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.13.

Amicus Therapeutics Trading Down 4.3 %

Shares of FOLD traded down $0.50 during trading on Wednesday, reaching $11.24. 6,337,131 shares of the company traded hands, compared to its average volume of 2,724,595. The stock has a 50-day simple moving average of $11.15 and a 200-day simple moving average of $10.60. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The stock has a market cap of $3.33 billion, a PE ratio of -32.05 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. During the same quarter last year, the firm earned ($0.15) EPS. The firm's revenue for the quarter was up 34.0% on a year-over-year basis. On average, analysts anticipate that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.